{"version":"1.0","provider_name":"Die Papier","provider_url":"https:\/\/novanews.co.za\/diepapier","title":"Die nuwe MIV-medikasie \u2018nog te duur\u2019","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"fm64HdRvD0\"><a href=\"https:\/\/novanews.co.za\/diepapier\/die-nuwe-miv-medikasie-nog-te-duur\/\">Die nuwe MIV-medikasie \u2018nog te duur\u2019<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/novanews.co.za\/diepapier\/die-nuwe-miv-medikasie-nog-te-duur\/embed\/#?secret=fm64HdRvD0\" width=\"600\" height=\"338\" title=\"&#8220;Die nuwe MIV-medikasie \u2018nog te duur\u2019&#8221; &#8212; Die Papier\" data-secret=\"fm64HdRvD0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script>\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/\/# sourceURL=https:\/\/novanews.co.za\/diepapier\/wp-includes\/js\/wp-embed.min.js\n<\/script>\n","thumbnail_url":"https:\/\/novanews.co.za\/diepapier\/wp-content\/uploads\/2026\/06\/GettyImages-22805047_12778.jpg","thumbnail_width":1200,"thumbnail_height":800,"description":"Slegs 450 000 mense sal in die volgende twee jaar toegang h\u00ea tot die nuwe MIV- anti-retrovirale inspuitbare behandeling, Lenacapavir. Dit is \u2019n middel wat jy kan gebruik om te voorkom dat jy MIV opdoen en moet elke ses maande toegedien word. Dr. Jantjie Taljaard, \u2019n kenner van aansteeklike siektes aan die Universiteit Stellenbosch, s\u00ea [&hellip;]"}